Zenas Biopharma, Inc.
A clinical-stage biopharmaceutical company developing therapies for autoimmune diseases. Its lead candidate, obexelimab, is a bifunctional antibody that calms overactive B cells without destroying them, and it met its primary goal in a late-stage trial for the rare condition IgG4-related disease. Founded in 2020 by serial entrepreneur Lonnie Moulder, the company takes its name from the ancient Greek "Zenas," meaning "gift of Zeus."
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Enavate Sciences GP, LLC | 13D/AActivist | 4.9% | 3.25M | Aug 19, 2026 |
| Zebra Aggregator, LP | 13D/AActivist | 4.9% | 3.25M | Aug 19, 2026 |
| SR One Capital Management, LLC | 13D/AActivist | 7.7% | 5.04M | Aug 17, 2026 |
Not applicable. | ||||
| Simeon George | 13D/AActivist | 7.7% | 5.04M | Aug 17, 2026 |
Not applicable. | ||||
| SR One Capital Fund II Aggregator, LP | 13D/AActivist | 3% | 1.95M | Aug 17, 2026 |
Not applicable. | ||||
| SR One Capital Partners II, LP | 13D/AActivist | 3% | 1.95M | Aug 17, 2026 |
Not applicable. | ||||
| AMZL, LP | 13D/AActivist | 2.9% | 1.92M | Aug 17, 2026 |
Not applicable. | ||||
| SR One Capital SMA Partners, LP | 13D/AActivist | 2.9% | 1.92M | Aug 17, 2026 |
Not applicable. | ||||
| SR One Capital Opportunities Fund I, LP | 13D/AActivist | 1.8% | 1.17M | Aug 17, 2026 |
Not applicable. | ||||
| SR One Capital Opportunities Partners I, LP | 13D/AActivist | 1.8% | 1.17M | Aug 17, 2026 |
Not applicable. | ||||